Published in Stat Med on January 02, 1987
Randomized phase II designs. Clin Cancer Res (2009) 1.73
Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial. Stroke (2013) 1.08
Novel methodologic approaches to phase I, II, and III trials. Stroke (2013) 0.83
Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing? World J Gastroenterol (2010) 0.83
Conservative treatment of retinoblastoma: a prospective phase II randomized trial of neoadjuvant chemotherapy followed by local treatments and chemothermotherapy. Eye (Lond) (2015) 0.76
The futility study-Progress over the last decade. Contemp Clin Trials (2015) 0.75
Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med (1974) 2.77
A clinical review of bleomycin--a new antineoplastic agent. Cancer (1973) 2.53
The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev (1975) 2.10
Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med (1973) 2.01
Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Ann Intern Med (1973) 1.87
Projection from previous studies: a Bayesian and frequentist compromise. Control Clin Trials (1987) 1.77
Adriamycin-a review. J Natl Cancer Inst (1975) 1.68
Radiotherapy (2500 rad) for testicular leukemia: local control and subsequent clinical events: a Southwest Oncology Group study. Cancer (1980) 1.42
The chemotherapy of urologic cancer. Cancer (1975) 1.32
Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast. Cancer Treat Rev (1976) 1.31
Carboplatin: the clinical spectrum to date. Cancer Treat Rev (1985) 1.27
The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol (1972) 1.24
Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res (1975) 1.22
Patient registration in a cooperative oncology group. Control Clin Trials (1980) 1.22
Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc Natl Acad Sci U S A (2000) 1.22
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med (1983) 1.19
Risk of radiation-related subsequent malignant tumors in survivors of Ewing's sarcoma. J Natl Cancer Inst (1979) 1.19
Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res (1986) 1.17
Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol (1993) 1.17
The dilemma of adjuvant chemotherapy for osteogenic sarcoma. Cancer Clin Trials (1980) 1.16
Cancer mortality in relatives of retinoblastoma patients. J Natl Cancer Inst (1984) 1.13
Management of locally advanced and disseminated breast cancer. Lancet (1981) 1.13
Surgery plus adjuvant chemotherapy--a review of therapeutic implications. I. Breast cancer. Cancer Chemother Pharmacol (1980) 1.11
A review of chemotherapy in gastric cancer. Cancer (1974) 1.09
An overview of the 1978 international meeting on comparative therapeutic trials. Biomedicine (1978) 1.08
Epidemiologic association between Gonorrhea and prostatic carcinoma. Urology (1975) 1.08
A comparison of the quality of participation of community affiliates and that of universities in the Northern California Oncology Group. J Clin Oncol (1983) 1.07
Single and combination nonhormonal chemotherapy in breast cancer. Cancer (1972) 1.06
Adjuvant chemotherapy in lung cancer: review and prospects. Cancer (1977) 1.02
Glutamine antagonists in chemotherapy. Adv Pharmacol Chemother (1970) 1.01
Hexamethylmelamine. An evaluation of its role in the therapy of cancer. Cancer (1976) 1.00
A staging system for histiocytosis X: a Southwest Oncology Group Study. Cancer (1981) 0.99
Management of trials in the development of cancer chemotherapy. Br J Cancer (1978) 0.99
Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma. Cancer Treat Rev (1974) 0.98
Single-agent cis-platinum therapy for advanced ovarian cancer. Obstet Gynecol (1981) 0.98
5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma. Eur J Cancer (1972) 0.97
Is lymphangiography worthwhile?. Int J Radiat Oncol Biol Phys (1979) 0.97
Nafoxidine--an antiestrogen for the treatment of breast cancer. Cancer (1976) 0.96
Editorial: Large-bowel cancer-The current status of treatment. J Natl Cancer Inst (1976) 0.94
Patterns of failure in small cell carcinoma of the lung. Cancer (1982) 0.92
Characterization of prostatic carcinoma among blacks: a preliminary report. Cancer Chemother Rep (1975) 0.92
Combination chemotherapy of advanced Hodgkin's disease. A review. Cancer (1974) 0.91
Standardization of cumulative failure rates. Demography (1975) 0.91
A method to detect excess risk of disease in structured data: cancer in relatives of retinoblastoma patients. Genet Epidemiol (1984) 0.90
Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol (1987) 0.89
Streptozotocin and metastatic insulinoma. Ann Intern Med (1971) 0.89
Characterization of prostatic carcinoma among blacks: a continuation report. Cancer Treat Rep (1977) 0.89
Squamous cell carcinoma of the pyriform sinus. Laryngoscope (1982) 0.88
Investigational drugs under study by the United States National Cancer Institute. Cancer Treat Rev (1976) 0.88
Surgery for common epithelial tumors of the ovary. Cancer (1981) 0.88
The nitrosoureas--thoughts for the future. Cancer Treat Rep (1976) 0.88
The chemotherapy of prostatic adenocarcinoma. Ann Intern Med (1980) 0.87
An overview of the status of the nitrosoureas in other tumors. Cancer Chemother Rep 3 (1973) 0.87
Cisplatin chemotherapy for disseminated endometrial cancer. Obstet Gynecol (1982) 0.87
Antiestrogens in the treatment of breast cancer. Cancer Treat Rev (1976) 0.86
Population-based study of small-cell lung cancer. J Clin Oncol (1985) 0.86
Significance of the 48-hour plasma level in high-dose methotrexate regimens. Cancer Clin Trials (1978) 0.86
Clinical comparison of the nitrosoureas. Cancer (1975) 0.86
The integration of chemotherapy into combined modality treatment of solid tumors. VIII. Cervical cancer. Cancer Treat Rev (1977) 0.86
The California breast cancer law and government-mandated patient education. CA Cancer J Clin (1982) 0.86
The integration of chemotherapy into a combined modality approached to cancer therapy. V. Squamous cell cancer of the head and neck. Cancer Treat Rev (1975) 0.86
Perspectives on research in gynecologic oncology. Cancer (1976) 0.86
Hexamethylmelamine: an evaluation of its role in the treatment of ovarian cancer. Am J Obstet Gynecol (1979) 0.86
Hexamethylmelamine--a new drug with activity in solid tumors. Eur J Cancer (1973) 0.85
Cancer chemotherapy: new developments and changing concepts. Drugs (1980) 0.85
Favorable response to maintenance therapy of second or subsequent remissions in childhood acute lymphocytic leukemia. Cancer (1980) 0.85
Endodermal sinus tumor of the ovary: the M. D. Anderson experience. Obstet Gynecol (1983) 0.85
Single-agent chemotherapy for recurrent carcinoma of the cervix. Cancer Clin Trials (1980) 0.84
Comparative evaluation of urographic contrast media, inulin, and 99mTc-DTPA clearance methods for determination of glomerular filtration rate in clinical transplantation. Transplantation (1989) 0.84
Chemotherapy in advanced breast cancer. Int J Radiat Oncol Biol Phys (1978) 0.83
1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review. Adv Cancer Res (1972) 0.83
Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. J Clin Oncol (1984) 0.83
Predictive probability early termination plans for phase II clinical trials. Biometrics (1979) 0.83
The chemotherapy of head and neck cancer. Semin Oncol (1977) 0.83
Long-term survival in childhood acute leukemia: "late" relapses. Med Pediatr Oncol (1979) 0.83
Gastric cancer: current status of treatment. J Natl Cancer Inst (1977) 0.83
A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancer. Gynecol Oncol (1983) 0.83
Methyl-CCNU inclinical cancer therapy. Cancer Treat Rev (1974) 0.83
Fibroblast implantation enhances wound healing as indicated by breaking strength determinations. Otolaryngology (1979) 0.82
A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma. Cancer (1985) 0.81
New drugs on the horizon in bronchogenic carcinoma. Cancer (1972) 0.81
Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole. Cancer Res (1983) 0.81
The interpretation of trials: combined hormonal therapy and chemotherapy in disseminated breast cancer. Breast Cancer Res Treat (1981) 0.81
Chromomycin A3, mithramycin, and olivomycin: antitumor antibiotics of related structure. Adv Pharmacol Chemother (1975) 0.81
Topical human fibroblast interferon for acute adenoviral conjunctivitis. Graefes Arch Clin Exp Ophthalmol (1987) 0.81
Integration of chemotherapy into combined modality treatment of solid tumors. 1. The overall strategy. Cancer Treat Rev (1974) 0.80
Some thoughts on experimental models and their clinical correlations. Eur J Cancer (1975) 0.80
Adjuvant chemotherapy in osteogenic sarcoma: the triumph that isn't? J Clin Oncol (1984) 0.80
Cancer treatment today and its impact on drug development, with special emphasis on the phase II clinical trial. J Natl Cancer Inst (1976) 0.80
New chemotherapeutic agents--bleomycin and adriamycin. CA Cancer J Clin (1975) 0.80
Current therapies in osteosarcoma. Cancer Treat Rev (1975) 0.80
The impact of lymph node status on survival in cervical carcinoma. Int J Radiat Oncol Biol Phys (1981) 0.80
Chemotherapy and genitourinary oncology. I. Bladder cancer. Cancer Treat Rev (1978) 0.80
Methodology of data reporting in advanced breast cancer trials. Cancer Chemother Pharmacol (1979) 0.79
Immunotherapy of cancer in man: current status and prospectus. Ann N Y Acad Sci (1976) 0.79
Single-agent therapy for Hodgkin's disease. Arch Intern Med (1973) 0.79
Radiation necrosis of the mandible: a 10 year study. Part II. Dental factors; onset, duration and management of necrosis. Int J Radiat Oncol Biol Phys (1980) 0.78
Vincristine and prednisone vs vincristine, L-asparaginase, and prednisone for second remission induction of acute lymphocytic leukemia in children. Med Pediatr Oncol (1979) 0.78
Cyclophosphamide in solid tumors. Cancer Treat Rev (1975) 0.78
Toxoplasma gondii: survival time and variability in mouse host strains. Exp Parasitol (1977) 0.78